The Oral Protease Inhibitor (PF-07321332) Protects Syrian Hamsters against Infection with SARS-CoV-2 Variants of Concern

The authors reported that PF-332 exerted equipotent in vitro activity against the four SARS-CoV-2 variants of concerns and that it could completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface.